NASDAQ:DMAC DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis $5.91 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$5.92 +0.01 (+0.25%) As of 05/22/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About DiaMedica Therapeutics Stock (NASDAQ:DMAC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DiaMedica Therapeutics alerts:Sign Up Key Stats Today's Range$5.77▼$5.9850-Day Range$5.57▼$7.2952-Week Range$3.47▼$10.42Volume87,854 shsAverage Volume167,386 shsMarket Capitalization$318.43 millionP/E RatioN/ADividend YieldN/APrice Target$12.33Consensus RatingModerate Buy Company Overview DiaMedica Therapeutics, Inc. (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need. DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival. DiaMedica has advanced DM199 through early‐stage clinical trials to assess safety, tolerability and preliminary efficacy. In parallel, the company is exploring additional indications for DM199, including diabetic kidney disease, leveraging its mechanism of action to address vascular and inflammatory pathways implicated in renal dysfunction. Headquartered in Minneapolis, Minnesota, DiaMedica operates primarily in the United States while engaging with regulatory authorities and research collaborators to support its clinical programs. As a NASDAQ‐listed entity, the company maintains a corporate strategy centered on building a proprietary pipeline, advancing clinical milestones and pursuing partnerships that can accelerate development and broaden global reach. DiaMedica is led by President and Chief Executive Officer Atul Koria, whose background spans drug development and strategic alliances in the biotechnology sector. Under his guidance, the company continues to focus on advancing DM199 through the clinic, with the goal of delivering innovative therapeutic options for patients suffering from stroke, kidney disease and other central nervous system disorders.AI Generated. May Contain Errors. Read More DiaMedica Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreDMAC MarketRank™: DiaMedica Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 777th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingDiaMedica Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDiaMedica Therapeutics has a consensus price target of $12.33, representing about 108.7% upside from its current price of $5.91.Amount of Analyst CoverageDiaMedica Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about DiaMedica Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for DiaMedica Therapeutics are expected to decrease in the coming year, from ($0.86) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DiaMedica Therapeutics is -8.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DiaMedica Therapeutics is -8.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiaMedica Therapeutics has a P/B Ratio of 6.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DiaMedica Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.57% of the float of DiaMedica Therapeutics has been sold short.Short Interest Ratio / Days to CoverDiaMedica Therapeutics has a short interest ratio ("days to cover") of 34.7, which indicates bearish sentiment.Change versus previous monthShort interest in DiaMedica Therapeutics has recently increased by 2.66%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDiaMedica Therapeutics does not currently pay a dividend.Dividend GrowthDiaMedica Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for DiaMedica Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added DiaMedica Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.00% of the stock of DiaMedica Therapeutics is held by insiders.Percentage Held by Institutions10.12% of the stock of DiaMedica Therapeutics is held by institutions.Read more about DiaMedica Therapeutics' insider trading history. Receive DMAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DMAC Stock News HeadlinesDiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke TrialMay 20, 2026 | finance.yahoo.comDiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke TrialMay 20, 2026 | businesswire.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.May 25 at 1:00 AM | Brownstone Research (Ad)DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Recommendation of "Moderate Buy" by AnalystsMay 18, 2026 | americanbankingnews.comH.C. Wainwright Keeps Their Buy Rating on Diamedica Therapeutics (DMAC)May 16, 2026 | theglobeandmail.comDiaMedica (DMAC) Q1 2026 Earnings TranscriptMay 8, 2026 | fool.comDiaMedica outlines ReMEDy2 interim analysis by end of 2026 with potential 300-700 patient resample sizeMay 7, 2026 | seekingalpha.comDiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comSee More Headlines DMAC Stock Analysis - Frequently Asked Questions How have DMAC shares performed this year? DiaMedica Therapeutics' stock was trading at $7.96 at the beginning of 2026. Since then, DMAC stock has decreased by 25.8% and is now trading at $5.91. How were DiaMedica Therapeutics' earnings last quarter? DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) announced its earnings results on Wednesday, May, 6th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.02. Read the conference call transcript. When did DiaMedica Therapeutics IPO? DiaMedica Therapeutics (DMAC) raised $18 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO. Who are DiaMedica Therapeutics' major shareholders? DiaMedica Therapeutics' top institutional shareholders include Sei Investments Co. (0.21%), Bank of New York Mellon Corp (0.21%), Kalehua Capital Management LLC (0.12%) and Renaissance Technologies LLC (0.10%). Insiders that own company stock include Jan Stahlberg, Koch Thomas Von, David J Wambeke, Randall Michael Giuffre, Dietrich John Pauls and Scott Kellen. View institutional ownership trends. How do I buy shares of DiaMedica Therapeutics? Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DiaMedica Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that DiaMedica Therapeutics investors own include NVIDIA (NVDA), ADMA Biologics (ADMA), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX), Ardelyx (ARDX) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/06/2026Today5/25/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 10 days, DMAC's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DMAC CIK1401040 Webwww.diamedica.com Phone(763) 496-5454FaxN/AEmployees20Year Founded2000Price Target and Rating Average Price Target for DiaMedica Therapeutics$12.33 High Price Target$14.00 Low Price Target$11.00 Potential Upside/Downside+108.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$32.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-77.15% Return on Assets-69.23% Debt Debt-to-Equity RatioN/A Current Ratio9.11 Quick Ratio9.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book6.72Miscellaneous Outstanding Shares53,880,000Free Float51,189,000Market Cap$318.43 million OptionableOptionable Beta0.99 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:DMAC) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
